← Volver a la portada
Asia · Mercados regionales · Yicai Global

China’s Akeso Sinks After US FDA Rejects License Application for Its Cancer Drug

Publicado por Yicai Global · China hace 9 h
China’s Akeso Sinks After US FDA Rejects License Application for Its Cancer Drug
China’s Akeso Sinks After US FDA Rejects License Application for Its Cancer Drug · Yicai Global

Resumen detallado

(Yicai) Nov. 16 -- Akeso’s shares plunged after the Chinese pharmaceutical company said the Biologics License Application for its cancer immunotherapy was rejected by the United…

(Yicai) Nov. 16 -- Akeso’s shares plunged after the Chinese pharmaceutical company said the Biologics License Application for its cancer immunotherapy was rejected by the United States Food and Drug Administration.

Akeso [HKG: 9926] was trading down 22.1 percent at HKD64.10 (USD8.16) as of 3.30 p.m. in Hong Kong today, after earlier dropping as much as 31.8 percent.

The first US application for ivonescimab was not approved, Akeso’s Chairwoman Michelle Xia said on a conference call yesterday. “This outcome is deeply disappointing for all of us, and it is also the most disappointing moment for me in the 14 years since the company was founded.”

Ivonescimab is a globally first-in-class PD-1/VEGF bispecific immuno-oncology drug independently developed by Akeso. Its clinical progress and commercialization outcomes will determine not only whether it can become a mainstream first-line treatment for lung cancer, but also whether PD-1/VEGF bispecific antibodies can challenge the benchmark status of PD-(L)1 monoclonal antibodies in cancer immunotherapy.

“The FDA determined that substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival improvement,” Akeso’s US partner Summit Therapeutics said in a statement yesterday. “The FDA indicated that the progression-free survival benefit in the absence of a statistically significant overall survival benefit does not support a positive benefit-risk profile in support of approval.”

The BLA was supported by data from HARMONi, ivonescimab’s first global, randomized, double-blind Phase III clinical trial, which served as an extension of the Chinese clinical trial. Xia explained on the call that the FDA clearly required that data from overseas populations meet the predefined statistically significant endpoint.

“The trial was not easy to advance, as there was a time gap between enrolling patients in China and abroad, ivonescimab was little known overseas at the start of the trial…

At the…

I…

Inicio del artículo, extracto de Yicai Global. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Yicai Global Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.yicaiglobal.com)

También te puede interesar